Daily Trades

I start this week with a quote - “It was the best of times, it was the worst of times, it was the age of wisdom, it was the age of foolishness, it was the epoch of belief, it was the epoch of incredulity, it was the season of light, it was the season of darkness, it was the spring of hope, it was the winter of despair.”
I have a simple cash skim for you today: HashiCorp (SYM: HCP) here at $32.50.
My dear mother has early-stage Alzheimer’s. What they say is true: it’s not pretty.
The biotech sector has sold off big time in the past 60 days, and Iovance (SYM: IOVA) has sold off along with it.
Back in the 90’s, Wall Street started putting pressure on Big Pharma to get better returns on their R&D spending.
Judging by all the emails we got over the weekend, most of you know Iovance Biotheutics (SYM: IOVA) won FDA approval for lifileucel.
Rumors of a takeover have surrounded Shockwave for years. This cardiovascular device maker would make a great fit for Johnson & Johnson, Medtronic or Boston Scientific.
I’m also thankful that I get to share some good news with you today regarding Iovance Biotherapeutics (SYM: IOVA).
I’ve been touting Iovance (SYM: IOVA) for so long, I may have to fall on my sword Japanese-style if it doesn’t work out.
Iovance (SYM: IOVA) jumped 20% today after announcing news that its lung cancer candidate LN-145 could be acceptable for a potential accelerated approval.

deal of the month

best growth stocks

Alliance

Bundle package – lifetime subscriptions for all products

Categories

Recent posts

Tags

Connect with Us

I start this week with a quote - “It was the best of times, it was the worst of times, it was the age of wisdom, it was the age of foolishness, it was the epoch of belief, it was the epoch of incredulity, it was the season of light, it was the season of darkness, it was the spring of hope, it was the winter of despair.”
I have a simple cash skim for you today: HashiCorp (SYM: HCP) here at $32.50.
My dear mother has early-stage Alzheimer’s. What they say is true: it’s not pretty.
The biotech sector has sold off big time in the past 60 days, and Iovance (SYM: IOVA) has sold off along with it.
Back in the 90’s, Wall Street started putting pressure on Big Pharma to get better returns on their R&D spending.
Judging by all the emails we got over the weekend, most of you know Iovance Biotheutics (SYM: IOVA) won FDA approval for lifileucel.
Rumors of a takeover have surrounded Shockwave for years. This cardiovascular device maker would make a great fit for Johnson & Johnson, Medtronic or Boston Scientific.
I’m also thankful that I get to share some good news with you today regarding Iovance Biotherapeutics (SYM: IOVA).
I’ve been touting Iovance (SYM: IOVA) for so long, I may have to fall on my sword Japanese-style if it doesn’t work out.
Iovance (SYM: IOVA) jumped 20% today after announcing news that its lung cancer candidate LN-145 could be acceptable for a potential accelerated approval.

Get FREE Daily Stock Tips

Join and receive market insider stock picks, trade alerts and unique investing insights
This field is for validation purposes and should be left unchanged.
By clicking the "Subscribe" button you are accepting our Terms of Use and Privacy Policy.

Join Waitlist

We’re sorry, but due to the popularity of our services, we have reached our max number of subscribers and are not currently accepting more. If spots become available, we will be sure to contact you. Please join the waitlist below.
Thank You!

"*" indicates required fields

Name*
This field is for validation purposes and should be left unchanged.